Incorporating postprandial and fasting plasma glucose into clinical management strategies

Insulin

Volumn 3, Issue 1, 2008, Pages 17-27

  Bode, Bruce W ^a  

^a ATLANTA DIABETES ASSOCIATES   (United States)

Author keywords

diabetes; fasting plasma glucose; glycosylated hemoglobin; hyperglycemia; hypoglycemia; oral antidiabetic drug; postprandial glucose

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN SENSITIZING AGENT; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VILDAGLIPTIN;

ADJUVANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC DIET; DIET RESTRICTION; DRUG MECHANISM; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; LIFESTYLE MODIFICATION; LIVER METABOLISM; LONG TERM CARE; MEDICAL DECISION MAKING; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT SATISFACTION; QUALITY OF LIFE; RISK REDUCTION; SIDE EFFECT; TREATMENT PLANNING; WEIGHT GAIN;

EID: 40349106450     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(08)80006-1     Document Type: Article

References (81)

1. American Diabetes Association. Postprandial blood glucose. Diabetes Care 24 (2001) 775-778
2. Davidson J. Should postprandial glucose be measured and treated to a particular target?. Yes. Diabetes Care 26 (2003) 1919-1921
3. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
4. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 Suppl 1 (2007) 3-68
5. Robertson C. Physiologic insulin replacement in type 2 diabetes: Optimizing postprandial glucose control. Diabetes Educ 32 (2006) 423-432
6. Buse J. Should postprandial glucose be routinely measured and treated to a particular target?. No!. Diabetes Care 26 (2003) 1615-1618
7. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
8. The DECODE Study Group and the European Diabetes Epidemiology Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet 354 (1999) 617-621
9. DeFronzo R., Ferrannini E., and Simonson D. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38 (1989) 387-395
10. DeFronzo RA, Mandarino LJ. Chapter 9. Pathogenesis of type 2 diabetes mellitus.
11. (January 18, 2006). http://www.endotext.com/diabetes/diabetes6/diabetes6.htm Accessed
12. The American College of Endocrinology and the American Association of Clinical Endocrinologists Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus. Naive to therapy (type 2).
13. (December 27, 2006). http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf Accessed
14. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-tterm complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
17. Rohlfing C., Wiedmeyer H., Little R., et al. Defining the relationship between plasma glucose and HbA(1c): Analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 25 (2002) 275-278
18. Avignon A., Radauceanu A., and Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20 (1997) 1822-1826
19. Soonthornpun S., Rattarasarn C., Leelawattana R., and Setasuban W. Postprandial plasma glucose: A good index of glycemic control in type 2 diabetic patients having near-nnormal fasting glucose levels. Diabetes Res Clin Pract 46 (1999) 23-27
20. Erlinger T., and Brancati F. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. [published correction appears in Diabetes Care. 2002;25:249]. Diabetes Care 24 (2001) 1734-1738
21. Jovanovic-Peterson L., Peterson C., Reed G., et al., Maternal postprandial glucose levels and infant birth weight: The Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development-Diabetes in Early Pregnancy Study. Am J Obstet Gynecol 164 (1991) 103-111
22. Parretti E., Carignani L., Cioni R., et al. Sonographic evaluation of fetal growth and body composition in women with different degrees of normal glucose metabolism. Diabetes Care 26 (2003) 2741-2748
23. Carroll M., Izard A., Riboni K., et al. Fasting hyperglycemia predicts the magnitude of postprandial hyperglycemia: Implications for diabetes therapy. Diabetes Care 25 (2002) 1247-1248
24. Meyer C., Stumvoll M., Nadkarni V., et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 102 (1998) 619-624
25. Bonora E., Calcaterra F., Lombardi S., et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: Implications for treatment and monitoring of metabolic control. Diabetes Care 24 (2001) 2023-2029
26. Ceriello A. Postprandial. hyperglycemia and diabetes complications: Is it time to treat? Diabetes 54 (2005) 1-7
27. Barzilay J., Spiekerman C., Wahl P., et al. Cardiovascular disease in older adults with glucose disorders: Comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354 (1999) 622-625
28. Hanefeld M., Koehler C., Schaper F., et al. Postprandial plasma glucose is an independent risk factor for increased carotid intimamedia thickness in non-diabetic individuals. Atherosclerosis 144 (1999) 229-235
29. Temelkova-Kurktschiev T., Koehler C., Henkel E., et al. Post-challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23 (2000) 1830-1834
30. Esposito K., Giugliano D., Nappo F., Marfella R., and for the Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110 (2004) 214-219
31. Ceriello A., Taboga C., Tonutti L., et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-tterm simvastatin treatment. Circulation 106 (2002) 1211-1218
32. Ceriello A., Quagliaro L., Piconi L., et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53 (2004) 701-710
33. Leiter L., Ceriello A., Davidson J., et al., for the International Prandial Glucose Regulation (PGR) Study Group. Postprandial glucose regulation: New data and new implications. Clin Ther 27 Suppl 2 (2005) S42-S56
34. Chiasson J., Josse R., Gomis R., et al., for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
35. Chiasson J.-L., Josse R., Gomis R., et al., for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM Trial. JAMA 290 (2003) 486-494
36. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). [published correction appears in Lancet . 1998;352:1558]. Lancet 352 (1998) 854-865
37. Nathan D., Cleary P., Backlund J., et al., for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
38. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 (2002) 2563-2569
39. Goldberg R., Holvey S., Schneider J., and for the Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 19 (1996) 849-856
40. Simonson D., Kourides I., Feinglos M., et al., for the Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 20 (1997) 597-606
41. Kitabchi A., Kaminska E., Fisher J., et al. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. Am J Med Sci 319 (2000) 143-148
42. American Association of Clinical Endocrinologists and the American College of Endocrinology. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update. Endocr Pract 8 Suppl 1 (2002) 40-82
43. Gribble F., Manley S., and Levy J. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 24 (2001) 1221-1225
44. Schmitz O., Lund S., Andersen P., et al. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: A randomized double-blind study with repaglinide. Diabetes Care 25 (2002) 342-346
45. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: Data from a 5-year surveillance study. Diabetes Res Clin Pract 52 (2001) 193-204
46. ® miglitol tablets [package insert]. New York, NY: Pharmacia & Upjohn Company, Division of Pfizer Inc; 2004.
47. (January 2008). http://www.pfizer.com/files/products/uspi_glyset.pdf Accessed
48. JANUVIA™ (sitagliptin) tablets [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2007.
49. (January 2008). http://www.januvia.com/sitagliptin/januvia/consumer/pi/index.jsp Accessed
50. Mimori N., Terao S., and Holmes D. Vildagliptin improves glucose control as evidenced by HbA1c after 12 weeks therapy in Japanese patients with type 2 diabetes. Diabetes 55 Suppl 1 (2006) A125 Abstract 527-P
51. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 19 (2003) 635-641
52. Turner R., Cull C., Frighi V., Holman R., and for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
53. Hirsch I., Bergenstal R., Parkin C., et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 23 (2005) 78-86
54. Gerich J. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 163 (2003) 1306-1316
55. Monnier L. Is. postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest 30 Suppl 2 (2000) 3-11
56. DeWitt D., and Hirsch I. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 289 (2003) 2254-2264
57. Kuritzky L. Addition of basal insulin to oral antidiabetic agents: A goal-directed approach to type 2 diabetes therapy. MedGenMed 8 (2006) 34
58. Johnson J., Wolf S., and Kabadi U. . Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 156 (1996) 259-264
59. Peyrot M., Lauritzen T., et al., for the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
60. Polonsky W., Fisher L., Guzman S., et al. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care 28 (2005) 2543-2545
61. Snoek F. Breaking the barriers to optimal glycaemic control-what physicians need to know from patients' perspectives. Int J Clin Pract Suppl 129 (2002) 80-84
62. Dailey G. A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy. Formulary 40 (2005) 114-130
63. Miller C., Phillips L., Ziemer D., et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161 (2001) 1653-1659
64. Cefalu C., and Cefalu W. Controlling hypoglycemia in type 2 diabetes: Which agent for which patient?. J Fam Pract 54 (2005) 855-862
65. American Association of Clinical Endocrinologists. State of diabetes in America.
66. (May 9, 2007). http://www.aace.com/newsroom/press/2005/FINALDataReport.pdf Accessed
67. Quattrin T., Belanger A., Bohannon N., Schwartz S., and for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 27 (2004) 2622-2627
68. Skyler J., Weinstock R., Raskin P., et al., for the Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care 28 (2005) 1630-1635
69. Hollander P., Blonde L., Rowe R., et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 27 (2004) 2356-2362
70. Weiss S., Cheng S., Kourides I., et al., for the Inhaled Insulin Phase II Study Group. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: A randomized controlled trial. Arch Intern Med 163 (2003) 2277-2282
71. DeFronzo R., Bergenstal R., Cefalu W., et al., for the Exubera Phase III Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial. Diabetes Care 28 (2005) 1922-1928
72. Rosenstock J., Zinman B., Murphy L., et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: A randomized, controlled trial. Ann Intern Med 143 (2005) 549-558
73. Barnett A., Dreyer M., Lange P., and Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 29 (2006) 1818-1825
74. Barnett A., Dreyer M., Lange P., and Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 29 (2006) 1282-1287
75. ®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 1 diabetes (T1DM). Diabetes 55 Suppl 1 (2006) A26 Abstract 110-OR
76. ®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes 55 Suppl 1 (2006) A26 Abstract 109-OR
77. Rosenstock J., Cappelleri J., Bolinder B., and Gerber R. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 27 (2004) 1318-1323
78. Simonson D., Hayes J., Turner R., and Testa M. Treatment satisfaction and preferences in type 2 diabetes: A randomized trial of oral agents versus inhaled insulin. Diabetes 50 Suppl 2 (2001) A131 Abstract 528-P
79. Simonson D., Turner R., Hayes J., et al. Improving quality of life in type 2 diabetes when Exubera is added after failure on metformin: A multicenter international trial. Diabetologia 47 Suppl 1 (2004) A311-A312 Abstract 865
80. Jones M. Therapies for diabetes: Pramlintide and exenatide. Am Fam Physician 75 (2007) 1831-1835
81. DeFronzo R., Ratner R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100